ReviewNeurocritical care2026
Exploring the Role of Alpha Lipoic Acid in the Treatment of Traumatic Brain Injury: Pathways and Perspectives.
Review in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alpha Lipoic Acid Mitigates TBI-Induced Neuroinflammation by Regulating S100B/STIM Signaling via NF-ƙB Pathway.Molecular neurobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTraumatic brain injury (TBI) is known to be a critical health challenge with a significant number of hospital admissions. In addition to the primary injury and its complications, the secondary phase of the injury also causes numerous health issues. Neuroinflammation, oxidative stress (OS), and neuronal cell death are among the main outcomes of secondary injury. Although so far there are no drugs approved by the Food and Drug Administration for TBI's pharmacological treatment, numerous pharmaceutical compounds have been studied to help patients. Alpha lipoic acid (ALA), as a potent antioxidant agent, has been investigated for a considerable period.
methodsEligible original studies written in English on the effects of ALA in TBI were collected from PubMed, Embase, Scopus, Web of Science, and Google Scholar for clinical, in vivo, and in vitro studies.
resultsALA is able to enter the blood-brain barrier due to its distinctive combination of hydrophilic and hydrophobic characteristics, enabling it to directly affect brain regions. It acts as a cofactor for enzymes in mitochondria, helping in oxidative carboxylation and replenishing other antioxidants like glutathione. This improves the glutathione/glutathione disulfide ratio during cellular stress, hence reducing cell death. In addition, ALA regulates oxidative, inflammatory, and apoptotic pathways by controlling the activity of caspase 3, caspase 9, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and inflammatory proteins, including tumor necrosis factor and inducible nitric oxide synthase. These methods highlight the potential of ALA in decreasing neuronal damage and OS in brain-related illnesses, including TBI.
conclusionsBased on this review, it can be concluded that ALA can potentially be administered as a therapeutic option for patients with TBI. However, more studies and trials are required to adjust the optimum dosing of ALA for the treatment of patients.
Indexed as
Identifiers
41083749What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.